Trial Profile
Intravitreous Anti-VEGF vs. Prompt Vitrectomy for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic retinopathy; Vitreous haemorrhage
- Focus Therapeutic Use
- 15 Dec 2020 Primary endpoint (Visual Acuity Area Under the Curve), has not been met according to results published in the JAMA: the Journal of the American Medical Association
- 15 Dec 2020 Results published in the JAMA: the Journal of the American Medical Association
- 01 Jun 2020 Status changed from active, no longer recruiting to completed.